Recent studies have demonstrated that introduction of hTERT in combination with SV40 large T antigen (LT), small t antigen (st), and H-rasV12 suffices to transform many primary human cells. In human mammary epithelial cells (HMECs) expressing elevated c-Myc, activated H-Ras is dispensable for anchorage-independent growth. Using this system, we show that st activates the PI3K pathway and that constitutive PI3K signaling substitutes for st in transformation. Moreover, using constitutively active versions of Akt1 and Rac1, we show that these downstream pathways of PI3K synergize to achieve anchorage-independent growth. At lower levels of c-myc expression, activated PI3K also replaces st to complement H-rasV12 and LT and confers both soft agar growth and tumorigenicity. However, elevated c-myc expression cannot replace H-rasV12 for tumorigenesis. These observations begin to define the pathways perturbed during the transformation of HMECs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1535-6108(03)00088-6DOI Listing

Publication Analysis

Top Keywords

human mammary
8
mammary epithelial
8
elevated c-myc
8
anchorage-independent growth
8
c-myc expression
8
epithelial cell
4
cell transformation
4
transformation activation
4
activation phosphatidylinositol
4
phosphatidylinositol 3-kinase
4

Similar Publications

miR-542-3p/PIK3R1 axis is involved in hsa_circ_0087104-mediated inhibition of esophageal squamous cell carcinoma metastasis.

Am J Cancer Res

December 2024

Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou 310003, Zhejiang, China.

Esophageal squamous cell carcinoma (ESCC), the most predominant subtype of esophageal cancer, is notorious for its high lymph node metastatic potential and poor prognosis. Growing evidence has demonstrated crucial function of circRNAs in human malignancies. However, the knowledge of circRNAs in lymph node metastasis of ESCC is still inadequate.

View Article and Find Full Text PDF

Background Clinicians use prognostic biomarker/multi-gene-based tests for predicting recurrence in hormone receptor-positive/HER2-negative (HR+/HER2-) early-stage breast cancer (EBC). CanAssist Beast (CAB) uses the expression of five protein biomarkers in combination with tumor-specific parameters such as tumor size, histopathological grade, and lymph node status to predict the risk of distant recurrence within five years of diagnosis for patients with HR+/HER2-, EBC. The current study aimed to evaluate the impact of prognostic tests on adjuvant chemotherapy decisions by assessing the agreement between clinical and CAB risk stratification as low-risk (LR) or high-risk (HR) for distant recurrence.

View Article and Find Full Text PDF

Silicone breast implants (SBIs) are commonly used for breast reconstruction and cosmetic surgery. However, long-term complications associated with SBI, such as rupture and infection, require careful monitoring. Here, we report a case in which coronavirus disease 2019 infection led to immunosuppression and secondary bacterial infection, resulting in skin ulceration and eventual removal of the SBI.

View Article and Find Full Text PDF

Objective: To explore the prognosis-predictive influence of human epidermal growth factor receptor 2 (HER2)-low status in breast cancer patients after neoadjuvant therapy (NAT).

Methods: Consecutive patients with invasive breast cancer who underwent NAT and surgery from January 2009 to December 2020 at multiple centers were included. A modified CPS+EG scoring system that integrates HER2-low status, CPS+EGH was developed.

View Article and Find Full Text PDF

In this study, the copper(II) complex [Cu(chromoneTSC)Cl]•0.5HO•0.0625CHOH (where chromoneTSC = -Ethyl-2-((4-oxo-4H-chromen-3-yl)methylene)-hydrazinecarbothioamide) was synthesized and characterized; then used to carry out studies in combination with berberine chloride (BBC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!